Johnson & Johnson JNJ

NYS: JNJ | ISIN: US4781601046   6/11/2025
186,97 USD (+0,52%)
(+0,52%)   6/11/2025
Grafiek Johnson & Johnson Grafiek Johnson & Johnson

Johnson & Johnson in het nieuws

6 november 2025 · FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder · Persbericht

29 oktober 2025 · Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting · Persbericht

27 oktober 2025 · New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile · Persbericht

27 oktober 2025 · TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years · Persbericht

27 oktober 2025 · Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis · Persbericht

25 oktober 2025 · Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies · Persbericht

24 oktober 2025 · Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis · Persbericht

19 oktober 2025 · Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer · Persbericht

16 oktober 2025 · TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care · Persbericht

16 oktober 2025 · Bedrijfsnieuws uit Amerika · Bolero.be

Bank of America verhoogt winstverwachting en overtreft analistenramingen De Amerikaanse grootbank heeft in het derde kwartaal beter dan verwachte resultaten geboekt dankzij sterke prestaties in investment banking en een...

Profiel Johnson & Johnson

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.jnj.com

Hoofdzetel: New Brunswick, New Jersey vlag Verenigde Staten

Mijn selecties